APA (7th ed.) Citation

Hiddemann, W., Barbui, A., Canales Albendea, M., Cannell, P., Collins, G., Dürig, J., . . . Marcus, R. (2017). IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN. Hematological oncology, 35, 117. https://doi.org/10.1002/hon.2437_106

Chicago Style (17th ed.) Citation

Hiddemann, W., et al. "IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN." Hematological Oncology 35 (2017): 117. https://doi.org/10.1002/hon.2437_106.

MLA (9th ed.) Citation

Hiddemann, W., et al. "IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN." Hematological Oncology, vol. 35, 2017, p. 117, https://doi.org/10.1002/hon.2437_106.